NIH Highlighted Topic: Understanding and Combating Chronic Disease Burden: The Role of Trauma
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research proposals focused on understanding how trauma exposure contributes to chronic disease burden and identifying evidence-based strategies to prevent long-term physical and mental health outcomes associated with traumatic experiences. This highlighted topic supports multidisciplinary research exploring the biological, neurobiological, behavioral, cognitive, and social mechanisms linking trauma exposure to chronic disease development across the lifespan.
NIH is particularly interested in projects examining how trauma exposure increases risk for conditions such as PTSD, depression, cardiovascular disease, metabolic syndrome, diabetes, substance use disorders, and alcohol misuse. Companies developing behavioral health technologies, digital therapeutics, predictive analytics platforms, trauma assessment tools, AI-enabled healthcare solutions, remote monitoring systems, or personalized intervention platforms may be strong candidates for funding.
Areas of interest include trauma risk stratification, resilience and recovery modeling, longitudinal health monitoring, prevention and intervention strategies, substance use and alcohol misuse research, trauma-informed healthcare evaluation, health disparities research, women’s health, and translational behavioral health technologies. NIH is also encouraging rigorous scientific evaluation of commonly adopted trauma-related care approaches to determine effectiveness and long-term impact on health outcomes.
Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional follow-on funding and commercialization support depending on the project’s scope and translational potential.
This highlighted topic is supported by multiple NIH Institutes and Offices including the National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Aging (NIA), Office of Research on Women’s Health (ORWH), Office of Disease Prevention (ODP), and National Institute on Minority Health and Health Disparities (NIMHD), all of which are seeking scalable innovations that improve prevention, diagnosis, intervention, and long-term health outcomes for trauma-exposed populations.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of behavioral health technologies, digital therapeutics, predictive analytics platforms, trauma assessment tools, and intervention systems related to trauma exposure and chronic disease prevention.
Eligible activities may include:
AI and machine learning platforms for trauma risk prediction
Digital mental health and behavioral health intervention technologies
Trauma assessment, screening, and monitoring tools
Predictive analytics systems for chronic disease risk after trauma exposure
Remote patient monitoring and wearable health technologies
PTSD, depression, and substance use disorder intervention platforms
Alcohol misuse prevention and recovery support technologies
Resilience and recovery modeling systems
Personalized behavioral health and prevention solutions
Trauma-informed care evaluation and effectiveness research tools
Longitudinal health tracking and population health analytics platforms
Women’s health technologies addressing trauma-related chronic disease risk
Health disparities and community-based intervention technologies
Neurobiological and biomarker research platforms
Digital therapeutics supporting trauma recovery and prevention
Healthcare coordination and support systems for trauma-exposed populations
Prototype development, validation studies, and translational research
Commercialization planning, regulatory preparation, and implementation activities
Funding may also support personnel, software development, cloud infrastructure, AI model development, clinical validation studies, behavioral research, wearable sensor integration, data analytics, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable healthcare or behavioral health solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
